

CLAIM AMENDMENTS

Claims 1-8 (Canceled)

9. (Currently amended) A method of [influencing] reducing the activity of hyperactive T cells, which method comprises contacting hyperactive T cells selected from the group consisting of tumor antigen-specific, transplant-specific, allergen-specific and virus-specific T cells with at least one proteolytic enzyme selected from trypsin and papain and, optionally, rutoside.

10. (Canceled)

11. (Currently amended) The method of claim 9, wherein the hyperactive T cells are contacted with rutoside.

12. (Canceled)

13. (Currently amended) The method of claim [10] 9, wherein the method further comprises contacting the hyperactive T cells with bromelain and the hyperactive T cells are in an organism and are contacted with bromelain, papain and trypsin by administering to the organism 20 to 100 mg bromelain, 40 to 120 mg papain and 10 to 50 mg trypsin per dose unit.

14. (Currently amended) The method of claim [12] 11, wherein the method further comprises contacting the hyperactive T cells with bromelain and the hyperactive T cells are in an organism and are contacted with bromelain, papain and trypsin by administering to the organism 20 to 100 bromelain, 40 to 120 mg papain and 10 to 50 mg trypsin per dose unit.

15. (Currently amended) The method of claim [12] 11, wherein the method further comprises contacting the hyperactive T cells with bromelain and the hyperactive T

cells are in an organism and are contacted with bromelain, papain and rutoside by administering to the organism 90 mg bromelain, 120 mg papain and 100 mg rutoside x 3H₂O per dose unit.

16. (Currently amended) The method of claim 13, wherein the method further comprises contacting the hyperactive T cells with bromelain and the hyperactive T cells are in an organism and are contacted with bromelain, papain and rutoside by administering to the organism 90 mg bromelain, 120 mg papain and 100 mg rutoside x 3H₂O per dose unit.

17. (Currently amended) The method of claim 14, wherein the method further comprises contacting the hyperactive T cells with bromelain and the hyperactive T cells are in an organism and are contacted with bromelain, papain and rutoside by administering to the organism 90 mg bromelain, 120 mg papain and 100 mg rutoside x 3H₂O per dose unit.

18. (Currently amended) The method of claim [12] 11, wherein the method further comprises contacting the hyperactive T cells with bromelain and the hyperactive T cells are in an organism and are contacted with bromelain, trypsin and rutoside by administering to the organism 90 mg bromelain, 48 mg trypsin and 100 mg rutoside x 3H₂O per dose unit.

19. (Currently amended) The method of claim 9, which further comprises contacting the hyperactive T cells with α_2 -macroglobulin.

20. (Canceled)

21. (Currently amended) The method of claim 11, which further comprises contacting the hyperactive T cells with α_2 -macroglobulin.

22. (Canceled)

23. (Currently amended) The method of claim 13, which further comprises contacting the hyperactive T cells with α_2 -macroglobulin.

24. (Currently amended) The method of claim 14, which further comprises contacting the hyperactive T cells with α_2 -macroglobulin.

25. (Currently amended) The method of claim 15, which further comprises contacting the hyperactive T cells with α_2 -macroglobulin.

26. (Currently amended) The method of claim 16, which further comprises contacting the hyperactive T cells with α_2 -macroglobulin.

27. (Currently amended) The method of claim 17, which further comprises contacting the hyperactive T cells with α_2 -macroglobulin.

28. (Currently amended) The method of claim 18, which further comprises contacting the hyperactive T cells with α_2 -macroglobulin.